Cutaneous and pulmonary sarcoidosis in a Hong Kong Chinese woman with silicone breast prostheses

Chang, Kwok Chiu; Chan, Kin; Chong, Lai Yin; Lau, Kam-Shing; Tam, Cheuk‐Ming; Lam, Chak-Wah

doi:10.1046/j.1440-1843.2003.00447.x

Cited by 22 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another possible cause of cutaneous and pulmonary sarcoidosis was reported by Chang et al [37] who found granulomatous formation in papular skin lesions, superficial lymph nodes and in transbronchial biopsies in a middle-aged Chinese females who had silicone breast augmentation a few years earlier. They speculate that silicone elastomer from the implants may have leaked and caused the granulomatous reaction.…”

Section: Other Types Of Skin Lesionsmentioning

confidence: 85%

Skin manifestations in sarcoidosis

Eklúnd¹,

Rizzato²

2005

Sarcoidosis

View full text Add to dashboard Cite

Almost a century ago, the relationship of sarcoid infiltrations of the skin and granulomatous changes in other organs was recognised. Schaumann, in 1914, proposed that lupus pernio (fig. 1a-c) could be a manifestation of a generalised disease. Later on, a variety of skin manifestations have been described to occur more or less frequently. Lupus pernio indicates an unfavourable prognosis, whereas in the case of erythema nodosum (EN) (fig. 2), disease remission generally occurs within months or a few years [1-4]. The histopathological characteristics of the two findings are totally different, reflecting the variable clinical picture and outcome in this inflammatory disorder where the antigen(s) still are unknown [5, 6]. Beside these two extremes, there are a number of other more or less common skin lesions having either a maculopapular, subcutaneous, cicatricial or plaque character. In this chapter, a sharp distinction will be made between nonspecific lesions, i.e. erythema nodosum, and specific skin manifestations, e.g. lupus pernio. The frequency of skin lesions in sarcoidosis varies depending on the intensity by which they are looked for [7, 8], as well as on the ethnic background of the patients [5, 6]. In Scandinavia, about one-third of the patients born there will present with EN as part of Lö fgren's syndrome [2]. However, in Japanese patients, this syndrome is less common. In contrast, lupus pernio is very infrequent in Scandinavia, but more common among African Americans in the USA [5, 6]. On an average, y25% of sarcoidosis cases have cutaneous involvement, which may appear at any stage of the disease [5, 9, 10]. More recently, Yanardag et al. [7] reported a higher percentage (almost 33%) of skin manifestations among w500 Turkish patients. Roughly, 20% of them had EN. The frequency of reported specific cutaneous involvement in sarcoidosis ranges from 10-40%.

show abstract

Section: Other Types Of Skin Lesionsmentioning

confidence: 85%

Skin manifestations in sarcoidosis

Eklúnd¹,

Rizzato²

2005

Sarcoidosis

View full text Add to dashboard Cite

show abstract

“…193 The adjuvants associated with ASIAs include silicone, hyaluronic acid, 196 and mineral oil. 197 Several sarcoidosis-like reactions related to ASIAs have been reported after silicone breast implantation, [198][199][200][201] with resolution of the sarcoidosislike reaction after removal of the implant. 202 Multisystem granulomatous reactions related to ASIAs should be differentiated from local foreign body granulomatous reactions (eg, siliconomas).…”

Section: Implant-and Device-induced Sarcoid-like Reactionsmentioning

confidence: 99%

Drug-Induced Sarcoidosis-Like Reactions

Chopra

Nautiyal

Kalkanis

et al. 2018

Chest

147

139

View full text Add to dashboard Cite

A drug-induced sarcoidosis-like reaction (DISR) is a systemic granulomatous reaction that is indistinguishable from sarcoidosis and occurs in a temporal relationship with initiation of an offending drug. DISRs typically improve or resolve after withdrawal of the offending drug. Four common categories of drugs that have been associated with the development of a DISR are immune checkpoint inhibitors, highly active antiretroviral therapy, interferons, and tumor necrosis factor-α antagonists. Similar to sarcoidosis, DISRs do not necessarily require treatment because they may cause no significant symptoms, quality of life impairment, or organ dysfunction. When treatment of a DISR is required, standard antisarcoidosis regimens seem to be effective. Because a DISR tends to improve or resolve when the offending drug is discontinued, this is another effective treatment for a DISR. However, the offending drug need not be discontinued if it is useful, and antigranulomatous therapy can be added. In some situations, the development of a DISR may suggest a beneficial effect of the inducing drug. Understanding the mechanisms leading to DISRs may yield important insights into the immunopathogenesis of sarcoidosis.

show abstract

“…Silicone migration may follow these paths, but it may also spread retrogradally or along other pathways (14). Rare cases of pneumonitis have also been observed (15)(16)(17).…”

Section: Discussionmentioning

confidence: 99%